Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVE: To compare the prognostic performance of biomarkers soluble fms-like tyrosine kinase-1 (sFlt-1), Placental Growth Factor (PIGF), and sFlt-1/PIGF ratio as continuous values or as a binary cut-off of 38 for predicting preeclampsia (PE) within 7 days. DESIGN: Secondary analysis of a randomised clinical trial. SETTING: Oxford University Hospitals, Oxford, United Kingdom (UK). POPULATION: Pregnant women between 24+0 to 37+0 weeks of gestation with a clinical suspicion of preeclampsia. MAIN OUTCOME: Onset of preeclampsia within 7 days of the initial biomarker test. METHODS: Logistic regression model for onset of preeclampsia using: (i) sFlt-1 (ii) PIGF, (iii) sFlt-1/PIGF ratio (continuous), and (iv) sFlt-1/PIGF ratio as a cut-off above or below 38. RESULTS: Of the total 370 women, 42 (11.3%) developed PE within 7 days of screening. Models with sFlt-1 and sFlt-1/PIGF ratio (continuous) had greater overall performance than models with PIGF or with sFlt-1/PIGF ratio as a cut-off at 38 (R2: sFlt-1 = 55%, PIGF = 38%, sFlt-1/PIGF ratio = 57%, sFlt-1/PIGF ratio as cut-off at 38 model = 46%). The discrimination performance was the highest in sFlt-1 and sFlt-1/PIGF ratio (continuous) (c-statistic, sFlt-1 = 0.94, sFlt-1/PIGF ratio (continuous) = 0.94) models compared to PIGF or sFlt-1/PIGF cut-off models (c-statistic, PIGF = 0.87, sFlt-1/PIGF cut-off = 0.89). CONCLUSION: Models using continuous values of sFlt-1 only or sFlt-1/PIGF ratio had better predictive performance compared to a PIGF only or the model with sFlt-1/PIGF ratio as a cut-off at 38. Further studies based on a larger sample size are warranted to substantiate this finding.

Original publication

DOI

10.1186/s12884-022-04817-6

Type

Journal article

Journal

BMC Pregnancy Childbirth

Publication Date

27/06/2022

Volume

22

Keywords

INSPIRE trial, PIGF, Preeclampsia, Prognostic model, sFlt-1, Biomarkers, Female, Humans, Placenta Growth Factor, Pre-Eclampsia, Pregnancy, Prognosis, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor-1